The FDA agreed. On August 30, 2017, after a unanimous vote by an exuberant advisory committee (“potentially paradigm shifting”), the agency gave its … - Tony Robbins

" "

The FDA agreed. On August 30, 2017, after a unanimous vote by an exuberant advisory committee (“potentially paradigm shifting”), the agency gave its green light to June’s modified T cells for ALL — its first approval ever for a cell-based gene transfer therapy. The Novartis brand name is Kymriah, a play on “chimera.” In 2018, the FDA approved it to treat several types of non-Hodgkin’s lymphoma. (It joined Yescarta, a similar product from Kite Pharma.) Based on some promising trials,